DNAJB6 and neoplasm: Considering that tumor stage is a high-risk factor for LUAD prognosis in clinical practice, this result not only suggests that DNAJB6 mRNA may be used as a predictive biomarker for LUAD prognosis but also indicates the rationality of bioinformatic analysis and the cohort in this study.